[Multicenter clinical study of the effects of once daily administration of mepartricin 150.000 U. in benign prostatic hypertrophy].
The effects of partricin methyl ester, administered to 481 BPH patients at the dose of 150.000 U as a single administration at night for 90 days were studied in the course of a multicentre study. The favourable evolution of the objective and subjective symptomatologic parameters taken into consideration confirmed the efficacy of the substance used even by this mode of administration. The size of the patient sample ensured that reliable findings were obtained as regards the excellent safety of this form of dosage.
Pisani
E
E
Istituto di Urologia, Università degli Studi di Milano.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004361:Drug Tolerance; D006801:Humans; D008297:Male; D008613:Mepartricin / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D013997:Time Factors
D008613:Mepartricin
Studio clinico multicentrico degli effetti dell'ipertrofan cpr. nella IPB con monosomministrazione giornaliera di 150.000 U.